JCB logo
Accuri Cytometers
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published 10 December 2001. doi:10.1083/jcb.200106023
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 576K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JCB
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hanyu, A.
Right arrow Articles by Miyazono, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanyu, A.
Right arrow Articles by Miyazono, K.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

© The Rockefeller University Press, 0021-9525/2001/12/1017 $5.00
The Journal of Cell Biology, Volume 155, Number 6, December 10, 2001 1017-1028

Article

The N domain of Smad7 is essential for specific inhibition of transforming growth factor-ß signaling



Aki Hanyu1, Yasuhiro Ishidou1, Takanori Ebisawa1, Tomomasa Shimanuki1, Takeshi Imamura1 and Kohei Miyazono1,2

1 Department of Biochemistry, The Cancer Institute of the Japanese Foundation for Cancer Research (JFCR), Tokyo 170-8455, Japan
2 Department of Molecular Pathology, Graduate School of Medicine, University of Tokyo, Tokyo 113-0033, Japan

Address correspondence to Kohei Miyazono, Department of Biochemistry, The JFCR Cancer Institute, 1-37-1 Kami-ikebukuro, Toshima-ku, Tokyo 170-8455, Japan. Tel.: 81-35-394-3866. Fax: 81-33-918-0342. E-mail: miyazono-ind{at}umin.ac.jp

Inhibitory Smads (I-Smads) repress signaling by cytokines of the transforming growth factor-ß (TGF-ß) superfamily. I-Smads have conserved carboxy-terminal Mad homology 2 (MH2) domains, whereas the amino acid sequences of their amino-terminal regions (N domains) are highly divergent from those of other Smads. Of the two different I-Smads in mammals, Smad7 inhibited signaling by both TGF-ß and bone morphogenetic proteins (BMPs), whereas Smad6 was less effective in inhibiting TGF-ß signaling. Analyses using deletion mutants and chimeras of Smad6 and Smad7 revealed that the MH2 domains were responsible for the inhibition of both TGF-ß and BMP signaling by I-Smads, but the isolated MH2 domains of Smad6 and Smad7 were less potent than the full-length Smad7 in inhibiting TGF-ß signaling. The N domains of I-Smads determined the subcellular localization of these molecules. Chimeras containing the N domain of Smad7 interacted with the TGF-ß type I receptor (TßR-I) more efficiently, and were more potent in repressing TGF-ß signaling, than those containing the N domain of Smad6. The isolated N domain of Smad7 physically interacted with the MH2 domain of Smad7, and enhanced the inhibitory activity of the latter through facilitating interaction with TGF-ß receptors. The N domain of Smad7 thus plays an important role in the specific inhibition of TGF-ß signaling.

Key Words: TGF-ß; bone morphogenetic protein; Smad; receptor; signaling


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents